NCT05712538 - Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions

Cystic Fibrosis

Interventions

DRUG

ARCT-032

ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).

OTHER

Placebo

Normal saline

Trial Locations (1)

8011

New Zealand Clinical Research, Christchurch